LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia Pacific Region.

Publication

Author(s):

Pujari S, Srasuebkul P, Sungkanuparph S, Lim PL, Kumarasamy N, Chuah J, Kumar RN, Chen YM, Oka S, Choi JY, Lee MP, Phanuphak P, Kamarulzaman A, Lee C, Fujie Z, Ditangco R, Saphonn V, Sirisanthana T, Merati TP, Smith J, Law MG.

Pub Title:

Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia Pacific Region.

Pub Date:

Nov 1 2009

Pub Region(s):

Asia-Pacific

Journal Issue:

1

Page Number:
28-35

Journal:

Title: 
Journal of Antivirals and Antiretrovirals
Link: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875551/

PubMed: 20505782
Pub PDF: PDF icon 20505782.pdf

Abstract

OBJECTIVES: Regimens containing protease inhibitors (PI) are less commonly used in developing countries due to high cost and less availability. We evaluated characteristics of patients initiating PI-based therapy according to previous antiretroviral (ARV) exposure; factors associated with initiating a PI-containing regimen using newer versus older PIs, and proportion of patients with detectable viral loads (VL) after initiating a PI-based regimen.

METHODS: This analysis includes all patients who have initiated a PI-based regimen. ARV exposure was categorised: naïve (no previous ARV), 1st, 2nd, >/= 3rd switches; a switch was defined as starting or stopping any drug in a regimen. Newer PIs were defined as those approved by the US FDA after 1 January 2000. Detectable VL at 12 months was defined as VL >/= 400 copies/mL. Characteristics at PI initiation were evaluated. Logistic regression was used to determine factors associated with initiating a newer PI and detectable VL at 12 months after PI initiation.

RESULTS: 1106 patients initiated PI-based therapy; of these, 618 (56%) were naïve patients. Overall, 22% (176) of patients had detectable VL at 12 months following the PI initiation. Being from a high income country (vs. mid/low income, OR = 1.80, p = 0.034) were more likely to be associated with detectable VL.

CONCLUSION: The use of PIs in this cohort is dictated by accessibility and affordability issues particularly for the newer PIs. Short-term virological outcomes following PI-therapy in our cohort were good, and were associated with CD4 count at time of initiation.

PMID: 20505782 [PubMed]

PMCID: PMC2875551

 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Pujari S, Srasuebkul P, Sungkanuparph S, Lim PL, Kumarasamy N, Chuah J, Kumar RN, Chen YM, Oka S, Choi JY, Lee MP, Phanuphak P, Kamarulzaman A, Lee C, Fujie Z, Ditangco R, Saphonn V, Sirisanthana T, Merati TP, Smith J, Law MG. Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. J Antivir Antiretrovir. 2009 Nov 1;1(1):28-35. PubMed PMID: 20505782; PubMed Central PMCID: PMC2875551.